Taking time to get a second opinion on breast cancer treatment did not significantly alter the time to treatment, which still ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

After further evaluation, she was diagnosed with cholangiocarcinoma, or bile duct cancer, a rare and aggressive cancer that ...

Women diagnosed with DCIS face a threefold higher risk of breast cancer mortality. Learn the warning signs, treatment options ...

Analysts estimate that NeoGenomics will report an earnings per share (EPS) of $-0.01. The market awaits NeoGenomics's ...

A new national survey has revealed a surprising gap in public health knowledge: many Americans don’t realize that drinking ...

Analysts have recently evaluated Veracyte and provided 12-month price targets. The average target is $44.71, accompanied by a ...

The surgical treatment of mid-low rectal cancer poses greater technical challenges, and whether robotic surgery provides superior safety and efficacy compared to laparoscopic surgery remains ...

Telix has been shocked by the US Food & Drug Administration's rejection of marketing approval for its brain cancer diagnostic ...

NeoGenomics shares dropped 34% on April 29 after missing its Q1 revenue estimates. Check out why I view the stock price ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...